Bioporto - Rights issue and update on NGAL
Bioporto interview with CEO Tony Paré and CFO Niel A. Goldman about upcoming rights issue and status on NGAL.
Rights issue of DKK 59,4 mio. with pre-emptive rights. So far DKK 16,6 mio. or 28% has been subscribed by largest shareholders, management and entire board of directors. Subscription period starts the 6th. of June and last day 19th. of June. Trading in rights started the 1st. of June and last day of trading is the 15th. of June. Slides from this presentation and further details in danish, you will find at the Bioporto homepage under the menu "Investor Relations".
Listen to the interview here: https://www.inderes.dk/videos/bioporto-rights-issue
We will host a new event the 12th. of June with status on the rights issue. Both CEO Tony Paré and CFO Niel A. Goldman will participate. We will soon launch the link at https://hcandersencapital.dk/events/
Disclaimer:
HC Andersen Capital receives payment from Bioporto for a DigitalIR/Corporate Visibility agreement.
BioPorto
BioPorto är verksamma inom bioteknik. Bolaget tillverkar och marknadsför tester för diagnostisering av diverse allvarliga sjukdomar. Produktportföljen består av egenutvecklade antikroppsläkemedel som används för farmaceutisk bruk samt inom diverse forskningssammanhang. Produkterna återfinns på global nivå och används exempelvis vid behandling och analys av fetma, diabetes och diverse allergier.
Read more on company page